Pharmacological Properties ofN-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease-Reference-Cited by-同舟云学术

Pharmacological Properties ofN-(3,5-Diamino-6-chloropyrazine-2-carbonyl)-N′-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine Methanesulfonate (552-02), a Novel Epithelial Sodium Channel Blocker with Potential Clinical Efficacy for Cystic Fibrosis Lung Disease

Published:2008-01-24 Issue:1 Volume:325 Page:77-88
ISSN:0022-3565
Container-title:Journal of Pharmacology and Experimental Therapeutics
language:en
Short-container-title:J Pharmacol Exp Ther

Author:

Hirsh Andrew J.,Zhang Jim,Zamurs Andra,Fleegle Jacquelyn,Thelin William R.,Caldwell Ray A.,Sabater Juan R.,Abraham William M.,Donowitz Mark,Cha Boyoung,Johnson Kevin B.,St. George Judith A.,Johnson M. Ross,Boucher Richard C.

Publisher

American Society for Pharmacology & Experimental Therapeutics (ASPET)

Subject

Pharmacology,Molecular Medicine

Reference40 articles.

1. Effect of Amiloride on Sodium-Calcium Exchange Activity in Rat Cardiac Myocytes

2. Acute and Long-term Amiloride Inhalation in Cystic Fibrosis Lung Disease: A Rational Approach to Cystic Fibrosis Therapy

3. Abnormal ion content, hydration and granule expansion of the secretory granules from cystic fibrosis airway glandular cells

4. Cystic fibrosis: a disease of vulnerability to airway surface dehydration

5. Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures.

Cited by 82 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. ETD001: A novel inhaled ENaC blocker with an extended duration of action in vivo;Journal of Cystic Fibrosis;2024-06

2. Discovery and development of BI 1265162, an ENaC inhibitor for the treatment of cystic fibrosis;European Journal of Medicinal Chemistry;2024-02

3. Mutation-independent cystic fibrosis treatment by opening calcium-activated chloride channel with a novel GPR39 agonist, DS-1039;2023-06-15

4. Preclinical evaluation of the epithelial sodium channel inhibitor AZD5634 and implications on human translation;American Journal of Physiology-Lung Cellular and Molecular Physiology;2022-11-01

5. Small-molecule drugs for cystic fibrosis: Where are we now?;Pulmonary Pharmacology & Therapeutics;2022-02